

LETTER TO THE EDITOR

Patterns of heart injury in COVID-19 and relation to outcome

To the Editor,

We read with much interest the article "Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan, China" by Han et al as published in March 2020. In this retrospective, single-center study authors have discussed the role of acute cardiovascular injury marker including creatine kinase myocardial band (CK-MB), myoglobin, cardiac troponin I (cTnI), and NT-proBNP on the outcome of 273 patients with COVID-19 disease. Authors have suggested that elevated concentrations of these enzymes in venous blood were related to disease severity and poor outcome.¹ We believe that this topic is relevant and evolving. We have the following additional comments for further understanding of the disease and its various pathophysiological bases in cardiac involvement.

Nonischemic and ischemic myocardial injury has been attributed to be the two principle pathophysiological basis of acute cardiac injury in COVID-19 patients.² Of the two, nonischemic myocardial injury is predominant and is secondary to multiple secondary mechanisms. The various distinct mechanisms for nonischemic myocardial injuries that have been published in the literature are (a) cytokine storm as documented by significantly raised inflammatory markers, (b) secondary to hemophagocytic lymphohistiocytosis, (c) viral myocarditis with reports of progression to fulminant myocarditis, (d) stress cardiomyopathy, and (e) hypoxia-induced cardiac myocyte apoptosis.³⁻⁵


Markers of cardiac injury including CK-MB, myoglobin, lactate dehydrogenase, ultra-TnI, NT-proBNP, D-dimer are elevated in any of the above patterns of cardiac injury. However, in most studies of COVID-19 patients showing increased mortality, an elevated troponin I level has been uniformly associated with uncontrolled inflammation secondary to cytokine storm. This phenomenon of infection-related increased cytokine release is identified by an elevated plasma level of several inflammatory markers. Various inflammatory markers that are shown to be elevated in patients with COVID-19-related cardiac injury are C-reactive protein (CRP), procalcitonin, ferritin, D-dimer, Interleukin-2 (IL-2), Interleukin-7 (IL-7), granulocyte-colony stimulating factor, IgG-induced protein 10, chemokine ligand 3, and tumor necrosis α .^{2,3,6} Did the authors have the details of various inflammatory markers among their patients?

Not only that cytokine storm-related cardiac injury has been consistently reported in most studies, but it has also been identified to be predictors of complications like acute respiratory distress, acute kidney injury, the severity of illness, requirement of intensive care unit admission, and higher mortality.^{2,7,8}

CONFLICT OF INTERESTS

The authors declare that there are no conflict of interests.

Ajay Kumar Mishra MD¹ 

Kamal Kant Sahu MD¹ 

Amos Lal MD²

Jennifer Sargent DO³

¹Department of Internal Medicine, St Vincent Hospital, Worcester, Massachusetts

²Department of Pulmonology and Critical Care Medicine, Mayo Clinic, Rochester, New York

³Internal Medicine, Saint Vincent Hospital, University of Massachusetts Medical School, Worcester, Massachusetts

Correspondence

Dr. Ajay Kumar Mishra, MD, Department of Internal Medicine St Vincent Hospital, 123 summer street, Worcester, MA 01608.

Email: Ajay.Mishra@stvincenthospital.com

ORCID

Ajay Kumar Mishra  <http://orcid.org/0000-0003-4862-5053>

Kamal Kant Sahu  <http://orcid.org/0000-0002-0382-6882>

REFERENCES

- Han H, Xie L, Liu R, et al. Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan, China. *J Med Virol*. 2020;92(7):819–823.
- Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. *JAMA Cardiol*. 2020:e200950. <https://doi.org/10.1001/jamacardio.2020.0950>
- Clerkin Kevin J, Fried Justin A, Jayant Raikhelkar, et al. Coronavirus disease 2019 (COVID-19) and cardiovascular disease. *Circulation*. 2020; 141(20):1648–1655. <https://doi.org/10.1161/CIRCULATIONAHA.120.046941>
- Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. *J Am Coll Cardiol*. 2020;75(18):2352–2371. <https://doi.org/10.1016/j.jacc.2020.03.031>
- Sahu KK, Mishra AK, Lal A. Novel coronavirus (2019-nCoV): update on 3rd coronavirus outbreak of 21st century. *QJM Mon J Assoc Physicians*. 2020;113(5):384–386. <https://doi.org/10.1093/qjmed/hcaa081>
- Zheng Y-Y, Ma Y-T, Zhang J-Y, Xie X. COVID-19 and the cardiovascular system. *Nat Rev Cardiol*. 2020;17:259–260. <https://doi.org/10.1038/s41569-020-0360-5>
- Zhou B, She J, Wang Y, Ma X. The clinical characteristics of myocardial injury in severe and very severe patients with 2019 novel coronavirus disease. *J Infect*. 2020;81(1):147–178. <https://doi.org/10.1016/j.jinf.2020.03.021>
- Mishra AK, Sahu KK, Sargent J. Cardiac drugs and outcome in COVID-19 [published online ahead of print April 14, 2020]. *QJM*. 2020:hcaa127. <https://doi.org/10.1093/qjmed/hcaa127>